AZN241213C66000
- 1.52
- +0.05+3.40%
AstraZeneca Newsroom
AstraZeneca (AZN) Gets a Hold From Kepler Capital
Express News | Tracer Biotechnologies Announces Multi-Year Project With AstraZeneca
Tracer Biotechnologies Announces Agreement for Next-Generation Cancer Monitoring for Drug Development
Eli Lilly Reports Positive Data From Late-Stage Breast Cancer Study
TD Cowen Maintains AstraZeneca(AZN.US) With Buy Rating, Announces Target Price $95
TD Cowen Keeps Their Buy Rating on AstraZeneca (AZN)
AstraZeneca (AZN.US) and MSD (MRK.US) announce long-term results from phase 3 Olympia clinical trial
Lynparza is a “first-in-class” PARP inhibitor and the first synthetic lethal targeted therapy to target cells/tumors with homologous recombinant repair (HRR) defects (such as cells carrying BRCA1 and/or BRCA2 mutations).
AstraZeneca, Merck Report Positive Long-term Data for Lynparza
AstraZeneca Says 87.5% of Lynparza-treated Patients Alive at Six Years in Trial
Express News | Lynparza Shows Significant Survival Benefit In Early Breast Cancer In OlympiA Phase III Trial; Reduces Risk Of Death By 28% And Recurrence By 35% At Six Years, Becoming First PARP Inhibitor To Improve Survival In Early Breast Cancer
LYNPARZA (Olaparib) Demonstrated Clinically Meaningful Prolonged Survival Benefit in Early Breast Cancer in OlympiA Phase III Trial
Lynparza Demonstrated Clinically Meaningful Prolonged Survival Benefit in Early Breast Cancer in OlympiA Phase III Trial
Why Astrazeneca (AZN) Is a Top Value Stock for the Long-Term
AZN, Daiichi's ADC Gets FDA Breakthrough Tag for EGFR-Mutated NSCLC
AstraZeneca (AZN) Receives a Hold From Jefferies
Astrazeneca (AZN.US) has achieved breakthrough therapy designation for a potential blockbuster ADC.
Astrazeneca (AZN.US) has a potential blockbuster ADC that has been granted breakthrough therapy designation.
Merck Reports Mixed Results From Keytruda Ovarian Cancer Study
Astrazeneca, Daiichi Sankyo's Datopotamab Deruxtecan Granted Breakthrough Therapy Designation in US
AZN's Bladder Cancer SBLA for Imfinzi Gets FDA's Priority Tag
ASH 2024: AstraZeneca Set to Take a BiTE Out of Follicular Lymphoma Market